nitric oxide system is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-02. Numbers and descriptions here follow the published literature rather than marketing material.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
In collaboration with Professor Jack Henion at Cornell University and Dr. Peter Dawson at the National Research Council of Canada, the first application of liquid chromatography-mass spectrometry-mass spectrometry (LC-MS-MS) was demonstrated on the TAGA 6000 in 1982. This proof of concept led to the development of the heated nebulizer LC interface for APCI, using pneumatic nebulization to allow the full LC flow to enter the ion source. In 1983, LC-MS-MS using ion evaporation, a spray method similar to electrospray but compatible with higher flow rates of up to 1 mL/min, was demonstrated on the TAGA 6000 but was not commercialized. The API III LC-MS-MS system introduced in 1989 provided both ion spray (developed by Bruins, Covey and Henion at Cornell University) and heated nebulizer LC inlets on a triple quadrupole platform based on the TAGA 6000 architecture. It was the second commercial LC-MS in the market, and the first that provided electrospray ionization. The atmospheric pressure spray methods of electrospray, ion spray and APCI which helped to drive the burgeoning LC-MS market are now available on a wide variety of MS platforms and from a variety of vendors. In 1998, the cryopump API III platform began to be replaced with turbo-molecular-pumped single and triple quadrupole mass spectrometer products that evolved from the API 2000 (benchtop) and API 3000 to the current API 7500 series.
=== Sustainability === Food engineering has negative impacts on the environment, such as the emission of large quantities of waste and the pollution of water and air, which must be addressed by food engineers in the future development of food production and processing operations. Scientists and engineers are experimenting in different ways to create improved processes that reduce pollution, but these must continue to be improved in order to achieve a sustainable food supply chain. Food engineers must reevaluate current practices and technologies to focus on increasing productivity and efficiency, while reducing the consumption of water and energy, and decreasing the amount of waste produced.
Martha Sharp "Sunny" von Bülow (née Crawford; September 1, 1931 − December 6, 2008) was an American heiress and socialite. Her second husband, Claus von Bülow, was convicted in 1982 of attempting to murder her by insulin overdose, but the conviction was overturned on appeal. A second trial found him not guilty, after experts opined that there was no insulin injection and that her symptoms were attributable to overuse of prescription drugs. The story was dramatized in the book and film Reversal of Fortune. Sunny von Bülow lived almost 28 years in a persistent vegetative state, from December 1980 until her death in a New York City nursing home on December 6, 2008.
=== Zinc toxicity === Increased zinc consumption is another cause of copper deficiency. Zinc is often used for the prevention or treatment of common colds and sinusitis (inflammation of sinuses due to an infection), ulcers, sickle cell disease, celiac disease, memory impairment, and acne. Zinc is found in many common vitamin supplements and is also found in denture creams. Recently, several cases of copper deficiency myeloneuropathy were found to be caused by prolonged use of denture creams containing high quantities of zinc. Metallic zinc is the core of all United States currency coins, including copper-coated pennies. People who ingest many coins will have elevated zinc levels, leading to zinc-toxicity-induced copper deficiency and the associated neurological symptoms. This was the case for a 57-year-old woman diagnosed with schizophrenia. The woman consumed over 600 coins and started to show neurological symptoms such as unsteady gait and mild ataxia.
1962 Waksman Merck postdoc fellowship, USA. 1967 Humboldt assistant professorship stipend at the Max-Planck Institute, Munich, Germany. 1970 visiting professorship at the Weizmann Institute of Science, Rehovot, Israel. 1973 guest professorship in Dallas, Texas, USA. 1978 guest professorship (Japan Society for the Promotion of Science) in Japan. 1982–1986 Full Professor (Ordinarius) in biotechnology at The Federal Institute of technology, ETH Zurich, Switzerland. 1993 honorary visiting professorship in biochemistry at the University of Bath, UK. 1995 honorary visiting professorship in biochemistry at the Université Catholique de Louvain, Louvain-la-Neuve, Belgium. During these stays he collaborated with Nobel Prize winners Lynen, Waksman as well as with Professors Estabrook and Srere, Katchalski-Katzir and Wilchek, Fukui, Chibata, Suzuki, Rees and Creighton respectively.
Sources: en.wikipedia.org
Genetic screens conducted in Drosophila led to the identification of several proteins that play a central role in Notch signaling, including Enhancer of split, Master mind, Delta, Suppressor of Hairless (CSL), and Serrate. At the same time, the Notch gene was successfully sequenced and cloned, providing insights into the molecular architecture of Notch proteins and led to identification of Notch homologs in Caenorhabditis elegans (C. elegans) and eventually in mammals. In the early 1990s Notch was increasingly implicated as the receptor of a previously unknown intercellular signal pathway in which the Notch intercellular domain (NICD) is transported to the nucleus where it acts as a transcription factor to directly regulate target genes. The release of the NICD was found to be as a result of proteolytic cleavage of the transmembrane protein through the actions of the γ-secretase complex catalytic subunit Presenilin. This was a significant interaction as Presenilin is implicated in the development of Alzheimer's disease. This and further research into the mechanism of Notch signaling led to research that would further connect Notch to a wide range of human diseases.
=== Criminal justice and law enforcement === On April 1, 2019, Pritzker created Illinois's Youth Parole system. Pritzker signed into law Senate Bill 1890, whose goal is to crack down on human trafficking. It requires hospitality business owners to train their employees to recognize victims of trafficking and to teach them the protocols of reporting to authorities. It also establishes penalties for human trafficking, including a fine of up to $100,000 and a Class 1 Felony charge. While serving in the Illinois Senate, Barack Obama sponsored an initiative that would collect data on traffic stops. This was codified when Pritzker signed House Bill 1613 into law. It creates a task force to collect and analyze data on traffic stops to address racial disparities. The task force was to report to the governor and the General Assembly by March 1, 2022, and every three years thereafter. According to the governor's office, the 2019–20 budget funded two classes of Illinois State Police cadets. In July 2019, Pritzker signed a bill that increases penalties for drivers who got involved in a road incident with injuries while texting. Under this bill, a person who causes serious injuries due to driving while texting could be fined at least $1,000 and have their driver's license suspended for a year. The law took effect immediately. In the same month, he signed House Bill 2045, ending the practice of collecting a $5 copay for offsite medical and dental treatments from people detained at a juvenile correction facility. This took effect in January 2020.
World War I St. Mihiel Meuse-Argonne Lorraine 1918 World War II Sicily Naples-Foggia Normandy (with arrowhead) Rhineland (with arrowhead) Ardennes-Alsace Central Europe Armed Forces Expeditions Dominican Republic Grenada Panama Southwest Asia Defense of Saudi Arabia Liberation and Defense of Kuwait
Diē-dǎ (跌打) or Dit Da, is a traditional Chinese bone-setting technique, usually practiced by martial artists who know aspects of Chinese medicine that apply to the treatment of trauma and injuries such as bone fractures, sprains, and bruises. Some of these specialists may also use or recommend other disciplines of Chinese medical therapies if serious injury is involved. Such practice of bone-setting (正骨; 整骨) is not common in the West.
The word "parsley" is a merger of Old English petersilie (which is identical to the contemporary German word for parsley: Petersilie) and the Old French peresil. Both of these names are derived from Medieval Latin petrosilium, from Latin petroselinum, which is the latinization of the Greek πετροσέλινον, petroselinon, 'rock-celery', from πέτρα, petra, 'rock, stone' and σέλινον, selinon, 'celery'. Mycenaean Greek se-ri-no, in Linear B, is the earliest attested form of the word selinon.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.